Anixa Biosciences Inc Stock Price, News & Analysis

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the Chinese National Intellectual Property Administration for its breast cancer vaccine technology patent. This marks the company's first Chinese patent and will provide protection into the 2040s.

The patent, exclusively licensed from Cleveland Clinic, covers composition of matter protection for Anixa's novel breast cancer treatment and prevention approach. The vaccine targets human α-lactalbumin, a protein associated with lactation that is abnormally expressed in certain breast cancers.

This expansion is particularly significant as breast cancer has become the most commonly diagnosed cancer among women in China, with hundreds of thousands of new cases annually. The patent complements existing protection in the United States and other key global markets.

Anixa Biosciences (NASDAQ: ANIX) has announced the treatment of the second patient in the fourth cohort of its Phase 1 clinical trial for ovarian cancer CAR-T therapy. The trial, conducted in partnership with Moffitt Cancer Center, is evaluating a novel treatment targeting the follicle-stimulating hormone receptor (FSHR).

Patients in the fourth cohort are receiving 3 million CAR-positive cells per kilogram of body weight, a 30-fold increase from the initial dose. Notably, no dose-limiting toxicities (DLTs) have been observed in this cohort. The study focuses on adult women with recurrent ovarian cancer who have progressed after at least two prior lines of therapy, aiming to evaluate safety, determine maximum tolerated dose, and monitor clinical activity.

Anixa Biosciences (NASDAQ: ANIX) has secured a new U.S. patent (No. 12,384,826) for its innovative chimeric antigen receptor-T cell (CAR-T) technology, extending protection until 2045. The patent, issued by the USPTO, covers core methods and compositions of Anixa's CAR-T platform, which is specifically designed to tackle solid tumors.

The technology, currently in clinical trials at Moffitt Cancer Center for treating recurrent ovarian cancer, was originally granted to The Wistar Institute and exclusively licensed to Anixa. This patent adds to the company's growing intellectual property portfolio, strengthening its position in developing breakthrough immuno-oncology treatments.

Anixa Biosciences (NASDAQ: ANIX) announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Program at Moffitt Cancer Center, will present at the 13th Annual Ovarcoming Cancer Conference on September 18, 2025. Dr. Wenham, who serves as the principal investigator for Anixa's ongoing ovarian cancer CAR-T therapy Phase 1 clinical trial, will discuss advancements in ovarian cancer research and therapies.

The conference, held both virtually and in-person at the Briar Club in Houston, Texas, brings together survivors, caregivers, and medical professionals to discuss important developments in ovarian cancer treatment.

Anixa Biosciences (NASDAQ: ANIX) has initiated the transfer of the Investigational New Drug (IND) application for its breast cancer vaccine from Cleveland Clinic to support an upcoming Phase 2 trial. The vaccine, targeting α-lactalbumin protein, has shown promising results in Phase 1, with over 70% of patients demonstrating protocol-defined immune responses.

The vaccine is designed to target α-lactalbumin, a protein normally expressed during lactation but also present in many breast cancers, potentially offering both therapeutic and preventive benefits. Anixa has engaged Advyzom as its regulatory consultant to manage FDA interactions during the IND transfer process.

Anixa Biosciences (NASDAQ: ANIX) has received a Notice of Allowance from the Canadian Intellectual Property Office for a patent covering its breast cancer vaccine technology. The patent, exclusively licensed from Cleveland Clinic, provides composition-of-matter protection for their novel immunogenic approach in Canada.

The vaccine targets human α-lactalbumin, a protein expressed during lactation and in certain breast cancers. This technology addresses a significant market need, as breast cancer represents 25% of new cancer cases in Canadian women and 13% of female cancer deaths annually. The patent strengthens Anixa's international intellectual property portfolio and supports future regulatory and commercial efforts outside the U.S.

Anixa Biosciences (NASDAQ: ANIX) has been awarded U.S. Patent Number 12,370,244, extending protection for its breast cancer vaccine technology into the mid-2040s. The patent covers novel immunization methods using human α-lactalbumin protein, which is expressed during lactation and in certain breast cancers.

Developed in collaboration with Cleveland Clinic, this vaccine represents a pioneering approach to breast cancer prevention, targeting a significant unmet need. With 297,000 new cases of invasive breast cancer projected in 2025 and 43,000 expected deaths in the U.S., the technology addresses a potential multi-billion dollar market opportunity, particularly for women at risk of triple-negative breast cancer (TNBC).

Anixa Biosciences (NASDAQ: ANIX) announced the upcoming issuance of U.S. Patent Number 12,357,593 on July 15, 2025, strengthening its intellectual property portfolio for ovarian cancer vaccine technology. The patent covers methods of eliciting immune responses targeting anti-Müllerian hormone receptor, type II (AMHR2), a key target for ovarian cancer prevention and treatment.

The vaccine technology, developed in collaboration with Cleveland Clinic and the National Cancer Institute, focuses on preventing and treating ovarian cancer, particularly in high-risk populations with BRCA mutations or family history. The patent, issued to Cleveland Clinic with Anixa holding worldwide rights, includes methods for administering immunogenic compositions comprising nucleic acid encoding AMHR2 polypeptide.

Anixa Biosciences (NASDAQ: ANIX) has initiated dosing in the fourth cohort of its Phase 1 clinical trial for ovarian cancer CAR-T therapy. The new cohort will receive 3 million CAR-positive cells per kg of body weight, a 30-fold increase from the first cohort. The trial, conducted at Moffitt Cancer Center, showed no dose-limiting toxicities in the third cohort. The study evaluates a novel CAR-T therapy targeting the follicle-stimulating hormone receptor (FSHR), which is specifically expressed on ovarian cells and tumor vasculature. The trial enrolls adult women with recurrent ovarian cancer who have progressed after at least two prior therapies, focusing on safety, maximum tolerated dose, and efficacy monitoring. CEO Amit Kumar noted promising early efficacy signs despite the trial's primary focus on safety.